If you have been in this industry as long as I have, you know the cycle: you emerge from the chaos of JPM Week in San Francisco, still shaking the frost off your coat, and the first question from your C-suite isn't "what did we learn?"—it’s "where are we going next?" For the oncology-focused biotech, that almost always boils down to a head-to-head decision between the American Association for Cancer Research (AACR) Annual Meeting and the American Society of Clinical Oncology (ASCO) Annual Meeting.
I’ve seen too many BD teams blow their entire annual travel budget on both, only to realize by Wednesday of website the second conference that they were talking to the same three venture capitalists they already met at a Demy-Colton event in March. Let’s cut the fluff. Choosing between these isn't about "networking more"—it’s about capital formation, data maturity, and operational opportunity cost.
Understanding the Core DNA of the Meetings
Before you commit to a venue or a hotel Asembia AXS26 Summit block, you have to understand that these events serve fundamentally different functions. If you treat them both as "general oncology meetings," you are going to burn cash and return home with a pocketful of business cards that lead nowhere.
AACR: The "Bench-to-Bedside" Innovation Lab
AACR is for the scientists and the early-stage investors. This is where you go when you have preclinical data that needs validation from the smartest heads in the room. The conversation here is granular. It’s about molecular pathways, drug-target interactions, and new modalities like bispecifics or novel ADCs. If your company is trying to justify a valuation based on a platform or a proprietary discovery engine, AACR is your theater.
ASCO: The Clinical Reality Check
ASCO is where the rubber meets the road. It is a commercial, clinical, and regulatory behemoth. You don't go to ASCO to explain your mechanism of action to a room of twenty academics; you go to ASCO to present interim Phase I/II data to global oncologists and potential pharma partners looking for late-stage assets. If you don't have clinical-grade data that could impact a standard-of-care protocol, you are just background noise in a city (like Chicago) that is going to swallow your budget whole.
Opportunity Cost and the ROI of Presence
When I look at a conference strategy, I look at the "hidden" costs. It isn't just the registration fee. It’s the cost of pulling your Chief Medical Officer off the clinical trial for four days. It’s the time your BD lead spends in transit. Let’s compare the two from a strategy standpoint:
Factor AACR (The Lab) ASCO (The Clinic) Primary Audience PIs, Researchers, Early-Stage VC Oncologists, Pharma BD, Analysts Best For Preclinical data, platform tech Clinical data, commercial licensing Partnering Tooling Often fragmented, less formal High-volume, utilizes partneringONE Venue Impact Varies; usually high convention fatigue McCormick Place (Huge logistical hurdle)Partnering and Tech: Separating Signal from Noise
You’ll often see people brag about their "partnering volume" at these events. Take that with a massive grain of salt. A badge scan is not a term sheet. I have spent years managing calendars through partneringONE, and the reality is that the quality of your meetings is inversely proportional to how "busy" you feel. If you are rushing from a booth to a coffee shop in a different district, you aren't doing BD; you're doing cardio.
Speaking of tech—if you’ve spent any time on the registration portals for these massive conferences, you know the experience is an absolute nightmare. Between the mandatory CookieYes consent banners popping up every time you blink and the absolute gauntlet of Cloudflare Bot Management cookies (like __cf_bm, __cfruid, _cfuvid, and cf_clearance), these sites are designed for security and data harvesting, not for user experience. It’s a recurring annoyance, but it’s a necessary hurdle to navigate when you’re building your meeting schedule.
Geography Matters: Don’t Ignore the Neighborhood
One thing most consultants ignore is the "neighborhood fatigue." If you’re at ASCO in Chicago and you stay in the Loop but your meetings are at McCormick Place, you are going to lose two hours a day in transit. That’s two hours you could have spent in a private meeting room.
For 2026, look at the host city’s layout before you pick your hotel. If the conference is spread across a massive convention center, prioritize a hotel within walking distance. If I see a team trying to coordinate a partner meeting during lunch hour across a city that requires an Uber, I know they’ve already lost. Use events like those produced by Informa Connect or the specialized summits from Demy-Colton if you need smaller, more focused environments where the venue doesn't act as a barrier to the conversation.
Genomics and Multiomics: The Tech Trends to Watch
For the 2026 cycle, keep an eye on how precision medicine events are integrating multiomics into their programming. The days of simple genomics being the "hot new thing" are gone. Now, investors want to see the integration of spatial biology and single-cell analysis into your clinical narrative.
Spatial Biology: If you aren't showing how your drug affects the tumor microenvironment spatially, you aren't at the cutting edge. Liquid Biopsy Integration: Are you using ctDNA for early patient stratification? If so, feature this at AACR. Data Scaling: Investors are moving away from "cool science" toward "scalable insight." Show them how your platform creates a flywheel of data.Decision Framework: How to choose for 2026
If you're still on the fence, use this simple internal audit to guide your 2026 planning:
- Do you have a clinical read-out scheduled for mid-2026? If yes, go to ASCO. The exposure to the clinical community is non-negotiable. Is your core value proposition built on a unique biological insight or a new modality (e.g., a novel degrader)? If yes, AACR is the better forum to build technical credibility. Are you currently in a fundraising round? If you’re at the "early-stage seed/Series A" phase, AACR/Demy-Colton ecosystem events will give you more facetime with the right partners than the commercial frenzy of ASCO. Do you have a limited BD team? If you have two people or fewer, do not attempt both. Pick one and own it. A deep, high-quality engagement at one conference is worth more than a fragmented, exhausted presence at two.
Stop chasing the badge scans. Stop worrying about which booth looks cooler. Start looking at your asset's maturity level and map it to the event that matches the audience you need to convince. If you have the data, go to the clinic (ASCO). If you have the science, go to the lab (AACR). Everything else is just noise.